Kala Pharmaceuticals, Inc. (KALA) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Revenue Growth KALA has had growing revenue for the last 4 years
Price to Book (PBV) Ratio Undervalued price-to-book. KALA stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) KALA equity is higher than it's debt.
Return of Equity KALA has GREAT return of equity (1515.04%).
Revenue KALA has positive revenue for last 3 years

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Net Income Growth KALA has never had growing net income.
Net Income KALA never has positive net income for 2 years.
Dividend Yield KALA has low dividend yield (0%).
Return of Assets KALA has low return of asset (-92.82%).
Return of Invested Capital KALA has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-109,121,000 USD

Dividend

Financial Ratios

CEO

CEO Name

Mr. Mark Iwicki

Management

About Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Additional Information

Company name

Kala Pharmaceuticals, Inc.

Symbol

NASDAQ:KALA

Exchange

NASDAQ Global Select

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Address

490 ARSENAL WAY, SUITE 120
Watertown
MASSACHUSETTS
US
02476

Website

https://www.kalarx.com